The business of semi-synthetic cannabinoids has gone from grey area to controlled substance in little over a year. Spain added HHC, THC-O and ten further substances to Schedule II of Annex 1 of Royal Decree 2829/1977 through Order SND/380/2025, published in the official gazette on 22 April 2025 and in force the following day. In parallel, HHC came under international control on 6 December 2025, after the UN Commission on Narcotic Drugs voted that March to place it in Schedule II of the 1971 Convention. It is the first semi-synthetic cannabinoid to make that jump.
What Spain actually banned
The order did not stop at HHC. Schedule II also took in hexahydrocannabinol acetate (HHC-O), hexahydrocannabiphorol (HHCP) and its acetate (HHCP-O), delta-8 and delta-9-tetrahydrocannabiphorol (THCP), tetrahydrocannabiphorol acetate (THCP-O), tetrahydrocannabinol acetate (THC-O), delta-8 and delta-9-THC-C8, hydrocannabidiol (H4-CBD) and tetrahydrocannabinolic acid (delta-9-THCA).
Those last two names matter most to anyone operating in industrial hemp. H4-CBD is produced by hydrogenating CBD, and much of the catalogue built around it leaned precisely on its «hemp-derived» origin to justify the sale. That argument no longer holds: what counts is the molecule, not the plant it came from.
The schedule always trails the lab
The European Drug Report 2026 from the European Union Drugs Agency (EUDA) sets out the mechanism precisely: these substances are made from CBD extracted from low-THC cannabis and marketed as «legal» replacements for delta-9-THC. When HHC fell, the substitutes arrived — HHC-O and HHC-P — and the agency notes that the latter now appears to be fully synthetic. Production, initially imported from the United States, now also takes place inside Europe.
The EUDA also stresses that the effects of these compounds on humans remain poorly studied, and that reported adverse reactions range from mild discomfort to severe poisoning requiring hospital treatment. That is the public-health argument driving the regulatory response, country by country, without a harmonised European rule setting one criterion for all twenty-seven.
What it means for operators
- Inventory risk. A molecule entering a schedule turns stock into a liability overnight. Anyone trading novel cannabinoids needs withdrawal clauses and short rotation windows.
- Analysis, not labels. Enforcement works from the product’s real profile. Without a full cannabinoid panel and an accredited lab behind it, paperwork offers no protection.
- European fragmentation. Exporting within the EU means checking each member state’s schedule: what is tolerated in one market can be a criminal offence next door.
- Banking and payment rails. Financial service providers calibrate their risk appetite to these schedules, and they usually cut faster than regulators do.
- Where the margin sits. Naturally occurring cannabinoids absent from the Spanish schedule — CBG or CBN among them — are where the demand once served by HHC is moving.
A conversation heading to Bilbao
The lesson of these eighteen months is that regulatory arbitrage is no longer a sustainable business model in Europe: the gap between a new molecule and its scheduling is measured in months, not years. The companies that survive the cycle will be those that build compliance and analytics in from day one, rather than chasing the next acronym.
That is exactly the kind of decision under discussion at the International Cannabis Business Forum — Spannabis B2B Bilbao 2027, on 11 March 2027 at the BEC VIP Hall. Producers, laboratories, distribution and investment, in a single day built for closing deals. Check the tickets and book your B2B table to sit down with the counterparts that matter to you.